Market Overview

MetaStat Expands Therapeutic and Companion Diagnostic Intellectual Property Portfolio


MetaStat, Inc. (OTCQB:MTST), a personalized medicine company
developing therapeutic and diagnostic treatment solutions for cancer
patients, announced today it received from the United States Patent and
Trademark Office (USPTO), a notice of allowance for claims contained in
a divisional application (U.S. patent application 14/074,089) entitled
"Metastasis Specific Splice Variants of Mena and Uses Thereof in
Diagnosis, Prognosis and Treatment of Tumors." Additionally, MetaStat
has received from the European Patent Office (EPO), a notice of issuance
for patent EP 2 126 566 B1 entitled "Metastasis Specific Splice Variants
of Mena and Uses Thereof in Diagnosis, Prognosis and Treatment of

"Importantly, these patents provide additional protection for our
anti-metastatic therapeutic program and broader claims related to kit
and nucleic acid versions for our MenaINV companion
diagnostic assay," stated Douglas A. Hamilton, President and CEO of
MetaStat. "Expanding our intellectual property portfolio is a critical
component of our new Rx/Dx strategy focused on developing higher-value

European issued patent EP 2 126 566 B1 contains claims supporting the
therapeutic use of anti-mena isoform drugs in addition to diagnostic
use. The USPTO allowed additional claims related to kit based nucleic
acid versions of MetaStat's protein-based companion diagnostic tests.
MetaStat can increase patient access to the MenaINV companion
diagnostic test by developing a variety of nucleic acid and
protein-based formats using different instrument platforms giving
providers greater flexibility to run the test in their facility or at
MetaStat's centralized CLIA-approved laboratory.

About MenaINV Companion Diagnostic Test

Companion diagnostic tests provide oncologists with information
regarding patient's eligibility for cancer drugs and if the patient is
likely to benefit. MetaStat is developing the MenaINV
companion diagnostic test to select patients for treatment with our
anti-metastatic drug candidates, based on the Mena isoform drug target,
and to predict drug response to certain receptor tyrosine kinase (RTK)
inhibitors and taxane-based treatments.

About MetaStat, Inc.

MetaStat is a biotechnology company focused on discovering and
developing personalized therapeutic and diagnostic treatment solutions
for cancer patients. Our Mena isoform "driver-based" diagnostic
biomarkers also serve as novel therapeutic targets for anti-metastatic
drugs. MetaStat is developing therapeutic product candidates and paired
companion diagnostics based on a novel approach that makes the Mena
isoform protein a drugable target. Our core expertise includes an
understanding of the mechanisms and pathways that drive tumor cell
invasion and metastasis, as well as drug resistance to certain targeted
therapies and cytotoxic chemotherapies. MetaStat is based in Boston, MA.

Forward-Looking Statements

This press release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, and such
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. You
are cautioned that such statements are subject to a multitude of risks
and uncertainties that could cause future circumstances, events or
results to differ materially from those projected in the forward-looking
statements as a result of various factors and other risks, including
those set forth in the company's Form 10-K and its other filings filed
with the Securities and Exchange Commission. You should consider these
factors in evaluating the forward-looking statements included herein,
and not place undue reliance on such statements. The forward-looking
statements in this release are made as of the date hereof and the
company undertakes no obligation to update such statements.

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at